BUSINESS: Worldwide Vaccine Industry Up To 2027 – Key Drivers, Restraints, And Opportunities

dWeb.News Article from Daniel Webster dWeb.News

dWeb.News Article from Daniel Webster dWeb.News

by Daniel Webster, dWeb.News Publisher

DUBLIN, Oct. 13, 2021 /PRNewswire/ — The “Vaccine Market By Technology Type, Indication and End User and Geography – Global Forecast up to 2027” report has been added to’s offering.

The Vaccines Market is estimated to grow at the rate of 6.7% CAGR by 2027. The high prevalence of diseases that require vaccines and the increasing use of vaccines to prevent infections such as pneumonia and influenza are key factors driving the growth of the vaccine market. The government’s focus on immunization programs also helps to raise awareness about the safety of vaccines and their availability. The various technologies used in the development and introduction of vaccines are another factor that accelerates market growth.

However, market growth is slowed by the long time it takes to develop and introduce the vaccine. Vaccines, also known as immunizations or weakening of a disease, are administered to the body to create antibodies against it. Many diseases such as smallpox and polio have been eradicated by effective immunization. Vaccinations play a significant role in maintaining healthy people in many countries. Therefore, many regional disease prevention strategies embrace them.

The market’s largest share is held by the conjugate vaccine segment. This is due to increasing government support and increased investments by companies in conjugate vaccine research. Conjugate vaccines, which are used to prevent diseases in infants and adults, have fueled the segment growth.

The market is further segmented based on the indication, in which diphtheria, pertussis, & tetanus segment hold a significant share in the market. This segment holds the largest share due to an increase in the number of cases of these illnesses and the rising birth rate where they are most likely.

As per the market by end-user, the market is bifurcated into pediatrics, adults, and travelers. Due to the high demand for vaccines in infants (MMR vaccines and BCG vaccines) and DPT vaccines (since infants are more susceptible to diseases that vaccines are required), the pediatric segment holds a significant share of the market.

According to the geographical market, the market is divided into North America, Europe, Asia Pacific, and the rest of the world. The largest market share is held by North America. This is due to high levels of infectious disease and increased investments by both government and non-government organisations in vaccine development in this region.

In the present era, there are growing concerns about the spread of infectious diseases with the changing environment worldwide. These infectious diseases not only put pressure on the public’s health, but also impact global economies. The government of each country is concerned about the impact of new diseases like HIV, hepatitis and dengue. The government of the respective countries is also concerned about an increase in cases of certain diseases, such as malaria and cholera. The rise in the number of deadly infectious diseases and the upturn of these diseases is driving a significant growth in vaccines markets.

This report includes the company profiles of the Panacea Biotec Limited, Johnson & Johnson Services, Inc, VBI Vaccines Inc., Merck & Co., Inc., Astellas Pharma Inc., GlaxoSmithKline Plc, Sanofi S.A., PFIZER INC, NOVAVAX, INC., and Bavarian Nordic.

As a result, vaccines have emerged as an effective solution for the rising infectious diseases worldwide. Many governments invest heavily in vaccine development to combat the rising number of infectious diseases.

Several factors are presented in this report which are influencing the market growth and limiting the market. This report examines the market’s growth and the contribution of each segment.

The report contains profiles of key players in the market for vaccines and their strategies, such as product launches and company expansions.

Further, the penetration of the market in the various countries is also depicted in this report.

Key Topics Covered:

1. Executive Summary

2. Industry Outlook

3. Market Snapshot

4. Market characteristics
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO – Impact Analysis

5. Technology Type: Market Size & Analysis
5.1. Overview
5.2. Recombinant
5.3. Conjugate Vaccines
5.4. Live Attenuated Vaccines
5.5. Inactivated Vaccines
5.6. Toxoid Vaccines
5.7. Others

6. Indication: Market Size & Analysis
6.1. Overview
6.2. Pneumococcal Disease
6.3. Influenza
6.4. Human Papilloma Virus
6.5. Meningococcal Disease
6.6. Rotavirus
6.7. Varicella, Measles, Mumps, & Rubella
6.8. Diphtheria, Pertussis, & Tetanus
6.9. Polio
6.10. Hepatitis
6.11. Other

7. End-User: Market Size & Analysis
7.1. Overview
7.2. Pediatric
7.3. Adults
7.4. Travelers

8. Geography: Market Size & Analysis
8.1. Overview
8.2. North America
8.3. Europe
8.4. Asia Pacific
8.5. Rest of the World

9. Competitive Landscape
9.1. Competitor Comparison Analysis
9.2. Market Developments
9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
9.2.2. Product Launches and execution

10. Vendor Profiles
10.1. Panacea Biotec Limited
10.1.1. Overview
10.1.2. Financial Overview
10.1.3. Product Offerings
10.1.4. Developments
10.1.5. Business Strategy
10.2. Johnson & Johnson Services, Inc
10.2.1. Overview
10.2.2. Financial Overview
10.2.3. Product Offerings
10.2.4. Developments
10.2.5. Business Strategy
10.3. VBI Vaccines Inc.
10.3.1. Overview
10.3.2. Financial Overview
10.3.3. Product Offerings
10.3.4. Developments
10.3.5. Business Strategy
10.4. Merck & Co., Inc.
10.4.1. Overview
10.4.2. Financial Overview
10.4.3. Product Offerings
10.4.4. Developments
10.4.5. Business Strategy
10.5. Astellas Pharma Inc.
10.5.1. Overview
10.5.2. Financial Overview
10.5.3. Product Offerings
10.5.4. Developments
10.5.5. Business Strategy
10.6. GlaxoSmithKline Plc
10.6.1. Overview
10.6.2. Financial Overview
10.6.3. Product Offerings
10.6.4. Developments
10.6.5. Business Strategy
10.7. Sanofi S.A.
10.7.1. Overview
10.7.2. Financial Overview
10.7.3. Product Offerings
10.7.4. Developments
10.7.5. Business Strategy
10.8.1. Overview
10.8.2. Financial Overview
10.8.3. Product Offerings
10.8.4. Developments
10.8.5. Business Strategy
10.9.1. Overview
10.9.2. Financial Overview
10.9.3. Product Offerings
10.9.4. Developments
10.9.5. Business Strategy
10.10. Bavarian Nordic
10.10.1. Overview
10.10.2. Financial Overview
10.10.3. Product Offerings
10.10.4. Developments
10.10.5. Business Strategy

11. Analyst Opinion

12. Annexure

For more information about this report visit

Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

For more dWeb.News Business News:

The post BUSINESS: Worldwide Vaccine Industry Up To 2027 – Key Drivers, Restraints, And Opportunities appeared first on dWeb.News dWeb.News from Daniel Webster Publisher dWeb.News – dWeb Local Tech News and Business News

The post BUSINESS: Worldwide Vaccine Industry Up To 2027 – Key Drivers, Restraints, And Opportunities appeared first on dWeb.News dWeb.News from Daniel Webster Publisher dWeb.News – dWeb Local Tech News and Business News

dWeb.NewsRead More

Similar Posts